Bridge Biotherapeutics (XKRX:288330) ROCE % : -107.27% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bridge Biotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bridge Biotherapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -107.27%.

Bridge Biotherapeutics ROCE % Historical Data

The historical data trend for Bridge Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bridge Biotherapeutics ROCE % Chart

Bridge Biotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

39.24

-27.97

-49.78

-85.79

-110.88

Bridge Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-93.83	-92.15	-93.12	-187.42	-107.27

Bridge Biotherapeutics ROCE % Calculation

Bridge Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-42284.614	/	( ( (61455.226 - 7494.364)	+	(32683.098 - 10375.344) )	/ 2 )
	=	-42284.614	/	( (53960.862	+	22307.754)	/ 2 )
	=	-42284.614	/	38134.308
	=	-110.88 %

Bridge Biotherapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-21973.832	/	( ( (32683.098 - 10375.344)	+	(26308.588 - 7646.479) )	/ 2 )
	=	-21973.832	/	( ( 22307.754	+	18662.109 )	/ 2 )
	=	-21973.832	/	20484.9315
	=	-107.27 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Bridge Biotherapeutics (XKRX:288330) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bridge Biotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Bridge Biotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bridge Biotherapeutics (XKRX:288330) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bridge Biotherapeutics Inc (XKRX:288330) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

58, Pangyo - ro, Gyeonggi No. 303, 255 beongil Seas Tower in Bundang Pangyo, Seongnam-si, KOR, 13486

Website

http://www.bridgebiorx.com

Bridge Biotherapeutics Inc is a drug research and development company. It operates in the pharmaceutical and bio industry. The company has two pipeline clinical-stage products namely, BBT-401 and BBT-877.

Bridge Biotherapeutics (XKRX:288330) Headlines

No Headlines